

NORDIC VACCINE MEETING 2024

Copenhagen 12-13 September 2024, Radisson Blu Hotel

PRELIMINARY PROGRAMME

THURSDAY SEPTEMBER 12, 9.30-17.30

Themes: RS-virus, maternal vaccination and evaluation of new vaccines	
Registration Coffee & tea	8.30-9.30
Welcome to Nordic Vaccine Meeting 2024 Tyra Grove Krause, Executive Vice President, Epidemiological Infectious Disease Preparedness, Statens Serum Institut	9.30-10.00
Welcome day 1 Chairs of the Scientific Committee: Peter H.S. Andersen, Statens Serum Institut and Ida Glode Helmuth, Danish Health Authority	10.00-10.05
<p>Session 1. RS-virus: Burden of disease and new possibilities for prevention</p> <p>New RSV prevention tools have become available in the form of vaccines targeting both infants (via the pregnant mother) and the elderly as well as passive protection of infants from new monoclonal antibodies. What is the burden of RSV disease in different subpopulations and how do we make best and most cost-effective use of these new tools?</p> <p>Chair: Kirstine Moll Harboe, Danish Health Authority</p>	
The magnitude and severity of paediatric RSV infections in 2022-2023 Speaker: Ulrikka Nygaard , Clinical Associate Professor, Rigshospitalet Copenhagen University Hospital, Denmark	10.05-10.25
PROMISE (Preparing for RSV Immunization and Surveillance in Europe) Speaker: Hanna Nohynek , Chief Physician, Deputy Head, Unit Infectious Diseases Control and Vaccines, Department Health Security, Finnish Institute for Health and Welfare (THL)	10.25-10.45

Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies Speaker: TBA	10.45-11.05
Preventing RSV with monoclonal antibodies: experiences from Spain 2023/24 Speaker: Aurora Limia , Head of Area Immunization Programme, Ministry of Health, Spain	11.05-11.25
Status on RSV prevention and perspectives in the five Nordic countries Each Nordic country presents national plans for RSV prevention	11.25-12.00
Lunch break & poster viewing	12.00-13.00
<p>Session 2. Perspectives on maternal vaccination</p> <p>During the last 10-15 years a paradigm shift has happened from reluctance in offering vaccines to pregnant women to now offering routine vaccinations against an increasing number of diseases, some of which aim to protect the newborn and not the mother per se. Vaccination in pregnancy is considered safe for most vaccines but do health care providers and the pregnant women agree?</p> <p>Chair: Margrethe Greve Isdahl, Senior Physician, Infection Control And Vaccines, Institute of Public Health, Oslo, Norway</p>	
Pregnant women's attitudes towards vaccination in pregnancy Speaker: Bo Tarning Hansen , Senior Researcher, Public Health Institute, Oslo, Norway	13.00-13.20
Covid-19 vaccination in pregnancy – lessons learned from Sweden and Norway Speaker: Anne Örtqvist , Docent, Department for Clinical Epidemiology, Institute for Medicine, Solna, Karolinska Institute, Sweden	13.20-13.40
RSV vaccination in pregnancy to prevent RSV illness in infants Speaker: Beate Kampmann , Centre for Global Health, Charité - Universitätsmedizin Berlin, and London School of Hygiene and Tropical Medicine, London, UK	13.40-14.00
Pertussis vaccination in pregnancy, experiences from Denmark on vaccine effectiveness and safety Speaker: Peter H. S. Andersen , Senior Medical Officer, Unit Leader, Section for Vaccine Preventable Diseases, Statens Serum Institut	14.00-14.20

<p>Panel discussion:</p> <ul style="list-style-type: none"> ○ The paradigm shift from reluctance to recommending several vaccinations to pregnant women ○ Attitudes towards vaccination among pregnant women and relevant health personnel ○ Experience from the other vaccination programs (influenza, covid, pertussis) <p>Panel: Programme managers from each country and selected speakers</p>	14.20-14.50
<p>Round-up of session by chair: Margrethe Greve Isdahl</p>	14.50-15.00
<p>Session 3: Evaluating new vaccines for national programmes</p> <p>In recent years, new vaccines have been introduced at a faster pace and with higher costs than before, which puts pressure on health authorities to make sure national vaccination programmes are up-to-date and ensures an optimal public health potential of these new vaccines. So how do we select which vaccines to evaluate and how do we evaluate them in a critical but fair way?</p> <p>Chairs:</p> <p>Hanna Nohynek, Chief Physician, Deputy Head, Unit Infectious Diseases Control and Vaccines, Department Health Security, Finnish Institute for Health and Welfare (THL)</p> <p>Kari Johansen, Senior Consultant, Vaccine-preventable diseases, Public Health Agency Sweden.</p>	
<p>Introduction by chairs</p> <ul style="list-style-type: none"> - Nordic vaccination programmes – how are they similar and how are they different in terms of criteria for introducing new vaccines, funding, etc. - New vaccines in pipeline 	15.30-15.50
<p>Cost effectiveness analyses</p> <p>Speaker: Philippe Beutels, professor and director of the Centre for Health Economics Research & Modelling Infectious Diseases, University of Antwerp</p>	15.50-16.10
<p>Modelling to support decision making on vaccination programs</p> <p>Speaker: Simopekka Vänskä, Department of Vaccination and Immune Protection, Finnish Institute for Health and Welfare (THL)</p>	16.10-16.30
<p>Beyond cost-effectiveness: Ethics in vaccine assessment (TBC)</p>	16.30-16.50

Speaker: Jasper Littmann , Acting Department Director, Department for Method Development and Analytics, Division for Infection Control, Norwegian Institute of Public Health (FHI)	
Panel discussion	16.50-17.30
Dinner at Festsalen, Kosmopol, Fiolstræde 44, 1171 København K	19.00

FRIDAY SEPTEMBER 13, 9.30-15.00

Theme: Disparities in Vaccination Coverage and Vaccine Equity	
Coffee & tea	9.00-9.30
Introduction day 2 Ida Glode Helmuth and Cecilie Hald, Danish Health Authority	9.30-9.35
<p>Session 4: Addressing Disparities in Vaccination Coverage: Epidemiological Insights and Approaches to Reaching Underserved Populations</p> <p>Despite high overall vaccination coverage in the Nordic countries, significant disparities exist within certain subpopulations. This session will delve into the demographics of the unvaccinated and explore why these disparities occur. We will also discuss approaches to reaching underserved populations, examining barriers and drivers of vaccination adherence and presenting successful methods to mitigate these disparities.</p> <p>Chairs: Valtýr Stefánsson Thors, University of Iceland / Landspítali University Hospital and Bolette Søborg, Statens Serum Institut</p>	
Determinants of HPV non-vaccination Speaker: Emma Appelqvist , Public Health Agency of Sweden (Folkhälsomyndigheten)	9.35-9.55
Determinants for vaccination against pneumococcal disease, covid-19 and influenza in Denmark Speaker: Anne Christine Nordholm , Statens Serum Institut	09.55-10.15
Measuring the 7Cs of Vaccination Readiness in order to facilitate effective interventions Speaker: Lau Lilleholt Harpviken , University of Copenhagen	10.15-10.35

<p>VaxAtt project. Attitudes to the childhood vaccination program among people with different immigrant backgrounds (vs. non-immigrant).</p> <p>Speaker: Rebecca Gleditsch, Norwegian Institute of Public Health (FHI)</p>	10.35-10.55
TBA	10.55-11.15
Poster viewing	11.15-12.00
Lunch break	12.00-13.00
<p>Vaccination drivers and barriers amongst underserved groups during the covid-19 pandemic: how can we use our insights from the pandemic to plan behavioural and communication interventions to increase uptake of other vaccines?</p> <p>Speakers: Katrine Bach Habersaat and Siff Malue Nilsen, WHO Regional Office for Europe</p>	13.00-13.20
<p><u>Project overview - RIVER EU (river-eu.org)</u> – Reducing Inequalities in Vaccine uptake in the European Union – Engaging Underserved communities. Project aiming to increase MMR and HPV vaccine uptake amongst children and adolescents who are from ethnic, religious and cultural minorities.</p> <p>Speaker: Idil Hussein, Finnish Institute for Health and Welfare (THL)</p>	13.20-13.40
<p>Sweden’s work with the Tailoring Immunization Programmes (TIP) framework and regional implementation of TIP processes in local contexts</p> <p>Speaker: Asha Jama, Public Health Agency of Sweden (Folkhälsomyndigheten)</p>	13.40-14.00
<p>Panel discussion</p> <p>Chairs: Valtýr Stefánsson Thors, University of Iceland / Landspítali University Hospital and Bolette Søborg, Statens Serum Institut</p>	14.00-14.40
<p>Closure of NVM2024</p> <p>Wrap up and announcement of next NVM conference</p> <p>By: The Chairs of the Scientific Committee</p>	14.40-15.00